Innate Pharma SA (IPHYF)
OTHER OTC:IPHYF
Holding IPHYF?
Track your performance easily

Innate Pharma SA (IPHYF) Financial Statements

27 Followers

Innate Pharma SA Financial Overview

Innate Pharma SA's market cap is currently ―. The company's EPS TTM is $-0.455; its P/E ratio is -2.81; Innate Pharma SA is scheduled to report earnings on September 12, 2024, and the estimated EPS forecast is $-0.30. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Dec 22Jun 22Dec 21Jun 21
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT-----
EBITDA-----
Net Income Common Stockholders-----
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 92.46M$ 84.22M$ 123.35M$ 119.84M$ 119.32M
Total Assets$ 184.21M$ 207.86M$ 280.43M$ 267.50M$ 266.22M
Total Debt$ 47.54M$ 0.00$ 43.37M$ 44.25M$ 16.50M
Net Debt$ -44.92M$ -84.22M$ -79.98M$ -75.58M$ -102.82M
Total Liabilities$ 132.29M$ 156.44M$ 164.10M$ 160.06M$ 132.66M
Stockholders Equity$ 51.90M$ 379.64M$ 116.33M$ 107.44M$ 133.56M
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in USD

Innate Pharma SA Earnings and Revenue History

Innate Pharma SA Debt to Assets

Innate Pharma SA Cash Flow

Innate Pharma SA Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis